Navigating the Future: Rare Disease Diagnostics Market Trends and Forecast Insights, 2025 Edition

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Rare Disease Diagnostics Market Size Growth Forecast: What to Expect by 2025?
The market for diagnosing rare diseases has seen robust expansion in the past few years. It is forecasted to grow from $35.23 billion in 2024 to $38.22 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.5%. The remarkable growth in the previous period can be linked to an increase in the need for cloud-based diagnostic methods, concentrated efforts to boost efficiency, a rise in neurological diseases, an escalation in immunological disorders, and a hike in healthcare expenditure.

How Will the Rare Disease Diagnostics Market Size Evolve and Grow by 2029?
In the upcoming years, the market of rare disease diagnostics is projected to experience significant expansion. It is expected to reach a value of $56.23 billion with a Compound Annual Growth Rate (CAGR) of 10.1% in 2029. The expected escalation during the forecast period could be a result of factors such as the rising occurrence of rare diseases, enhanced government initiatives, a growing number of hospitals and diagnostic laboratories, the increase of hematology diseases, and the improvement of the healthcare structure. The advancement in genetic testing technologies, the emergence of both whole-genome sequencing and next-generation sequencing (NGS), broad investments, and strategic research partnerships are all significant trends anticipated during the forecast period.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

What Drivers Are Propelling the Growth of Rare Disease Diagnostics Market Forward?
The anticipated rise in rare diseases is likely to stimulate expansion in the rare disease diagnostics market. A rare disease is one that affects a minuscule portion of the population as compared to prevalent health issues. The diagnosis of these rare diseases plays a key role in managing the condition, identifying likely treatments, and circumventing unnecessary treatments that could potentially result in severe side effects, thereby paving the way for effective treatment. For instance, Health Match, an Australian digital health firm, reported in November 2022 that there are approximately 150 rare kidney conditions prevalent globally, with 60-80 cases per 100,000 people in the United States and Europe. Consequently, this surge in rare diseases serves as a catalyst for the growth of the rare disease diagnostics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

Which Emerging Trends Are Transforming the Rare Disease Diagnostics Market in 2025?
Technological advancements are a prime emerging trend in the market for rare disease diagnostics. To maintain their competitive edge, leading companies in this market are embracing innovative technologies. For instance, in April 2023, Centogene GmbH, a German firm specializing in rare diseases, unveiled CentoGenome, a solution offering whole genome sequencing for diagnosing rare and neurodegenerative ailments. This enhanced next-generation sequencing (NGS)-based assay provides whole genome sequencing (WGS) tests for a myriad of rare and neurodegenerative disorders, encapsulating virtually all disease-inducing variants within one test. Moreover, it boasts superior sensitivity in identifying Copy Number Variations (CNVs) associated with Spinal Muscular Atrophy (SMA), as well as complex disease-causing variations linked with Gaucher Disease (GD) and heightened susceptibility to GBA1-related Parkinson's Disease (PD). Critical to note is Centogenome's use of PCR (polymerase chain reaction)-free technology in areas of the genome typically difficult to sequence. This approach significantly reduces bias and improves the quality of sequencing data, contributing to an enhanced understanding of coding, regulatory, and intronic regions.

What Are the Key Segments in the Rare Disease Diagnostics Market?
The rare disease diagnostics market covered in this report is segmented -

1) By Test Type: Genetic Test, General Lab Test, Imaging Test
2) By Technology: Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays
3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample, Buccal Swab Sample, Blood, Saliva
4) By Disease Type: Gastroenterology Disease, Endocrine And Metabolism Disorders Disease, Hematology And Oncology Disease, Dermatology Disease, Cardiovascular Disorders, Neurology Disease
5) By End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories

Subsegments:
1) By Genetic Test: Whole Genome Sequencing, Targeted Gene Panels, Exome Sequencing, Carrier Testing
2) By General Lab Test: Blood Tests, Biochemical Assays, Urine Tests, Cytogenetic Tests
3) By Imaging Test: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scans, Ultrasound, X-Rays

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

Who Are the Key Players Shaping the Rare Disease Diagnostics Market's Competitive Landscape?
Major companies operating in the rare disease diagnostics market include Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Astellas Pharma Inc., Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio-Rad Laboratories Inc., Qiagen NV, BioMarin Pharmaceutical Inc., OPKO Health Inc., Sarepta Therapeutics Inc., Natera Inc., Invitae Corporation, Ultragenyx Pharmaceutical Inc., Travere Therapeutics Inc., BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., Agios Pharmaceuticals Inc., Orphazyme A/S, RareCyte Inc.

What Geographic Markets Are Powering Growth in the Rare Disease Diagnostics Market?
North America was the largest region in the rare disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12651

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.